

11. **Centers for Disease Control and Prevention (CDC).** Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. *MMWR Morb Mortal Wkly Rep.* 2009; 58: 256–260.
12. **Walker E, Lyman A, Gupta K, et al.** Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. *Clin Infect Dis.* 2016; 63: 960–965.
13. **Tinelli M, Cataldo MA, Mantengoli E, et al.** Epidemiology and genetic characteristics of extended-spectrum beta-lactamases-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. *J Antimicrob Chemother.* 2012; 67(12): 2982–2987.
14. **Toner L, Papa N, Aliyu SH, et al.** Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. *World J Urol.* 2016; 34(7): 1031–1037.
15. **Ozgun BC, Ekici M, Yuceturk CN, Bayrak O.** Bacterial colonization of double J stents and bacteriuria frequency. *Kaohsiung J Med Sci.* 2013; 29(12): 658–661.
16. **Kehinde EO, Rotimi VO, AlHunayan A, et al.** Bacteriology of urinary tract infection associated with indwelling J ureteral stents. *J Endourol.* 2004; 18(9): 891–896.
17. **Lojanapiwat B.** Colonization of internal ureteral stent and bacteriuria. *World J Urol.* 2006; 24(6): 681–683.
18. **Laralsla A, Medina Polo J, Alonsolsa M, et al.** Urinary Infections in Patients with Catheters in the Upper Urinary Tract: Microbiological Study. *Urol Int.* 2017; 98(4): 442–448.
19. **Cai T, Mazzoli S, Lanzafame P, et al.** Asymptomatic Bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI. *Pathogens.* 2016; 5(1): 4.
20. **Magyar A, Köves B, Nagy K, et al.** Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. *J Med Microbiol.* 2017; 66(6): 788–797.
21. **Gohel K, Jojera A, Soni S, et al.** Bacteriological Profile and Drug Resistance Patterns of Blood Culture Isolates in a Tertiary Care Nephrourology Teaching Institute. *BioMed Res Int.* 2014; 2014: 1–5.
22. **van der Donk CFM, Beisser PS, Hoogkamp Korstanje JAA, et al.** A 12 year (1998–2009) antibiotic resistance surveillance of *Klebsiella pneumoniae* collected from intensive care and urology patients in 14 Dutch hospitals. *J Antimicrob Chemother.* 2011; 66(4): 855–858.
23. **Stapleton PJ, Lundon DJ, McWade R, et al.** Antibiotic resistance patterns of *Escherichia coli* urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. *Ir J Med Sci.* 2017; 186(3): 733–741.
24. **European Centre for Disease Prevention and Control.** Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report 2019. Stockholm: ECDC; 2020.
25. **European Centre for Disease Prevention and Control.** Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2019 [Internet]. Stockholm: ECDC; 2020. Dostupné z: <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019>, 18. 11. 2020.
26. **Centers for Disease Control and Prevention.** National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP). 2019 AR Threats Report [Internet]. 2019. Dostupné z: <https://www.cdc.gov/drugresistance/Biggest-Threats.html>, 23. 11. 2021.
27. **Bonkat G, Bartoletti R, Bruyère R, et al.** Panel EAU Working Group on Urological Infections. EAU Guidelines on Urological infections. Edn. presented at the EAU Annual Congress Milan 2021. 978-94-92671-13-4. Publisher: EAU Guidelines Office. Place published: Arnhem, The Netherlands.
28. **Hrbáček J, Čermák P, Hanáček V, et al.** Prevalence uropatogenů v moči a spektrum jejich rezistence – analýza dat z jednoho pracoviště. *Ces Urol.* 2019; 23(4): 316–324.